Premarket Analysis: SCNX - Scienture Holdings Breakout NewsPurchased shares of SCNX at $2.89 after the company had a breakout, releasing news of partnering with Kindeva to launch the 10mg Rezenopy nasal spray for opioid overdose treatment. We're looking for a $4.92 retest, entering with a $2.22 stop loss on the Trade.
FINANCIAL NEWS:
7:41 AM EST, March 06, 2025 (Benzinga Newswire)
SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY® (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY® in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.
REZENOPY® is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids.
The addition of REZENOPY® to Scienture's product portfolio aligns with Scienture's mission to provide innovative treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose. As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts.
Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.
